Atherosclerosis: Lessons from LXR and the intestine

Trends in Endocrinology and Metabolism

Volumn 24, Issue 3, 2013, Pages 120-128

  Bonamassa, Barbara ^a   Moschetta, Antonio ^a,b,c,d  

^a Laboratory of Lipid Metabolism and Cancer   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Atherosclerosis; High density lipoprotein (HDL); Intestine; Liver X receptors (LXRs); Reverse cholesterol transport (RCT)

Indexed keywords

ABC TRANSPORTER A1; ACYL COENZYME A; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL (TOPIC); HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE; INTESTINE ABSORPTION; INTESTINE CELL; NIEMANN PICK DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ATHEROSCLEROSIS; ATP BINDING CASSETTE TRANSPORTER 1; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; HOMEOSTASIS; HUMANS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; INTESTINES; LIPOPROTEINS; MEMBRANE PROTEINS; ORPHAN NUCLEAR RECEPTORS; STEROL O-ACYLTRANSFERASE;

EID: 84875260304     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.10.004     Document Type: Review

References (120)

1. Lewington S., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839.
2. van der Steeg W.A., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J. Am. Coll. Cardiol. 2008, 51:634-642.
3. Di Angelantonio E., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
4. Briel M., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338:b92.
5. Khera A.V., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 2011, 364:127-135.
6. Paciaroni M., Bogousslavsky J. Statins and stroke prevention. Expert Rev. Cardiovasc. Ther. 2009, 7:1231-1243.
7. Venkateswaran A., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12097-12102.
8. Repa J.J., et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000, 289:1524-1529.
9. Repa J.J., et al. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 2002, 277:18793-18800.
10. Yu L., et al. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J. Biol. Chem. 2003, 278:15565-15570.
11. Duval C., et al. Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem. Biophys. Res. Commun. 2006, 340:1259-1263.
12. Zelcer N., et al. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.
13. Peet D.J., et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
14. Calkin A.C., Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1513-1518.
15. Repa J.J., et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-2830.
16. Schultz J.R., et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14:2831-2838.
17. Grefhorst A., et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 2002, 277:34182-34190.
18. Jakel H., et al. The liver X receptor ligand T0901317 down-regulates APOA5 gene expression through activation of SREBP-1c. J. Biol. Chem. 2004, 279:45462-45469.
19. Svensson S., et al. Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. EMBO J. 2003, 22:4625-4633.
20. Williams S., et al. X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. J. Biol. Chem. 2003, 278:27138-27143.
21. Zhang Y., et al. Liver LXRalpha expression is crucial for whole body cholesterol homeostasis and reverse cholesterol transport in mice. J. Clin. Invest. 2012, 122:1688-1699.
22. Altmann S.W., et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004, 303:1201-1204.
23. Davies J.P., et al. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem. 2005, 280:12710-12720.
24. Temel R.E., et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J. Clin. Invest. 2007, 117:1968-1978.
25. Yu L. The structure and function of Niemann-Pick C1-like 1 protein. Curr. Opin. Lipidol. 2008, 19:263-269.
26. Davis H.R., et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 2004, 279:33586-33592.
27. Tang W., et al. Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:448-454.
28. Tang W., et al. Genetic inactivation of NPC1L1 protects against sitosterolemia in mice lacking ABCG5/ABCG8. J. Lipid Res. 2009, 50:293-300.
29. -/- mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:841-849.
30. Clader J.W. The discovery of ezetimibe: a view from outside the receptor. J. Med. Chem. 2004, 47:1-9.
31. Garcia-Calvo M., et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. U.S.A. 2005, 102:8132-8137.
32. Weinglass A.B., et al. Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11140-11145.
33. Cohen J.C., et al. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1810-1815.
34. Fahmi S., et al. Functional characterization of genetic variants in NPC1L1 supports the sequencing extremes strategy to identify complex trait genes. Hum. Mol. Genet. 2008, 17:2101-2107.
35. Polisecki E., et al. Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J. Lipid Res. 2010, 51:1201-1207.
36. Martin B., et al. An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia. Nutr. Metab. Cardiovasc. Dis. 2010, 20:236-242.
37. Chan D.C., et al. Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clin. Endocrinol. (Oxf.) 2008, 69:45-51.
38. Berge K.E., et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000, 290:1771-1775.
39. Lee M.H., et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet. 2001, 27:79-83.
40. Hubacek J.A., et al. Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Hum. Mutat. 2001, 18:359-360.
41. Hirata T., et al. Molecular mechanisms of subcellular localization of ABCG5 and ABCG8. Biosci. Biotechnol. Biochem. 2009, 73:619-626.
42. Klett E.L., et al. Localization of ABCG5 and ABCG8 proteins in human liver, gall bladder and intestine. BMC Gastroenterol. 2004, 4:21.
43. Plosch T., et al. Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the Abcg5/8 transporter. J. Nutr. 2006, 136:2135-2140.
44. Yu L., et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:16237-16242.
45. Yu L., et al. Selective sterol accumulation in ABCG5/ABCG8-deficient mice. J. Lipid Res. 2004, 45:301-307.
46. -/- mice. Hepatology 2007, 45:998-1006.
47. Yu L., et al. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J. Biol. Chem. 2005, 280:8742-8747.
48. Yu L., et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest. 2002, 110:671-680.
49. Tang W., et al. Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice. Hepatology 2006, 44:1259-1266.
50. Gylling H., et al. Polymorphisms in the ABCG5 and ABCG8 genes associate with cholesterol absorption and insulin sensitivity. J. Lipid Res. 2004, 45:1660-1665.
51. Schmitz G., Langmann T. Structure, function and regulation of the ABC1 gene product. Curr. Opin. Lipidol. 2001, 12:129-140.
52. Fitzgerald M.L., et al. ABCA1 and amphipathic apolipoproteins form high-affinity molecular complexes required for cholesterol efflux. J. Lipid Res. 2004, 45:287-294.
53. Favari E., et al. The C-terminal domain of apolipoprotein A-I is involved in ABCA1-driven phospholipid and cholesterol efflux. Biochem. Biophys. Res. Commun. 2002, 299:801-805.
54. Kielar D., et al. Rapid quantification of human ABCA1 mRNA in various cell types and tissues by real-time reverse transcription-PCR. Clin. Chem. 2001, 47:2089-2097.
55. Vedhachalam C., et al. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J. Biol. Chem. 2007, 282:25123-25130.
56. Rust S., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 1999, 22:352-355.
57. Kathiresan S., et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 2008, 40:189-197.
58. Basso F., et al. Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J. Lipid Res. 2003, 44:296-302.
59. Timmins J.M., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 2005, 115:1333-1342.
60. Brunham L.R., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 2006, 116:1052-1062.
61. Glickman R.M., Green P.H. The intestine as a source of apolipoprotein A1. Proc. Natl. Acad. Sci. U.S.A. 1977, 74:2569-2573.
62. Wu A.L., Windmueller H.G. Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat. J. Biol. Chem. 1979, 254:7316-7322.
63. Van Eck M., et al. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:929-934.
64. de la Llera-Moya M., et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler. Thromb. Vasc. Biol. 2010, 30:796-801.
65. Wang N., et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:9774-9779.
66. Kennedy M.A., et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 2005, 1:121-131.
67. Tarling E.J., Edwards P.A. ATP binding cassette transporter G1 (ABCG1) is an intracellular sterol transporter. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:19719-19724.
68. Lee R.G., et al. Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates. J. Lipid Res. 2000, 41:1991-2001.
69. Joyce C., et al. Acyl-coenzyme A:cholesteryl acyltransferase 2. Curr. Opin. Lipidol. 1999, 10:89-95.
70. Buhman K.K., et al. Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat. Med. 2000, 6:1341-1347.
71. Degirolamo C., et al. LDL cholesteryl oleate as a predictor for atherosclerosis: evidence from human and animal studies on dietary fat. J. Lipid Res. 2009, 50(Suppl.):S434-S439.
72. Willner E.L., et al. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1262-1267.
73. Lee R.G., et al. Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ. Res. 2004, 95:998-1004.
74. -/- mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1814-1820.
75. Brown J.M., et al. Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. J. Biol. Chem. 2008, 283:10522-10534.
76. Alger H.M., et al. Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization. J. Biol. Chem. 2010, 285:14267-14274.
77. Nguyen T.M., et al. Cholesterol esterification by ACAT2 is essential for efficient intestinal cholesterol absorption: evidence from thoracic lymph duct cannulation. J. Lipid Res. 2012, 53:95-104.
78. Zhang J., et al. Tissue-specific knockouts of ACAT2 reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood. J. Lipid Res. 2012, 53:1144-1152.
79. Apfel R., et al. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell. Biol. 1994, 14:7025-7035.
80. Willy P.J., et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995, 9:1033-1045.
81. Janowski B.A., et al. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
82. Naik S.U., et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 2006, 113:90-97.
83. Mak P.A., et al. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J. Biol. Chem. 2002, 277:31900-31908.
84. Laffitte B.A., et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell. Biol. 2003, 23:2182-2191.
85. Luo Y., Tall A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 2000, 105:513-520.
86. Zhang Y., et al. Regulation of lipoprotein lipase by the oxysterol receptors, LXRalpha and LXRbeta. J. Biol. Chem. 2001, 276:43018-43024.
87. van der Veen J.N., et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 2009, 284:19211-19219.
88. Yasuda T., et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. 2010, 30:781-786.
89. Lo Sasso G., et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 2010, 12:187-193.
90. Sehayek E., Hazen S.L. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1296-1297.
91. Davis H.R., Veltri E.P. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J. Atheroscler. Thromb. 2007, 14:99-108.
92. Greenberg M.E., et al. Moderately decreased cholesterol absorption rates are associated with a large atheroprotective effect. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1745-1750.
93. Gomez-Garre D., et al. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br. J. Pharmacol. 2009, 156:1218-1227.
94. Brown B.G., Taylor A.J. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?. N. Engl. J. Med. 2008, 358:1504-1507.
95. Kastelein J.J., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 2008, 358:1431-1443.
96. Taylor A.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med. 2009, 361:2113-2122.
97. Villines T.C., et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J. Am. Coll. Cardiol. 2010, 55:2721-2726.
98. Califf R.M., et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am. Heart J. 2010, 159:705-709.
99. Engelking L.J., et al. Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes. J. Lipid Res. 2012, 53:1359-1368.
100. Xie Y., et al. Liver X receptor agonist modulation of cholesterol efflux in mice with intestine-specific deletion of microsomal triglyceride transfer protein. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1624-1631.
101. -/- mice. J. Lipid Res. 2004, 45:1429-1436.
102. Wu J.E., et al. Hepatic ABCG5 and ABCG8 overexpression increases hepatobiliary sterol transport but does not alter aortic atherosclerosis in transgenic mice. J. Biol. Chem. 2004, 279:22913-22925.
103. Basso F., et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J. Lipid Res. 2007, 48:114-126.
104. Brunham L.R., et al. Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels. Circ. Res. 2006, 99:672-674.
105. Nijstad N., et al. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology 2011, 140:1043-1051.
106. Temel R.E., et al. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab. 2010, 12:96-102.
107. Kruit J.K., et al. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology 2005, 128:147-156.
108. van der Velde A.E., et al. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology 2007, 133:967-975.
109. Jakulj L., et al. Ezetimibe stimulates faecal neutral sterol excretion depending on abcg8 function in mice. FEBS Lett. 2010, 584:3625-3628.
110. Cheng S.H., Stanley M.M. Secretion of cholesterol by intestinal mucosa in patients with complete common bile duct obstruction. Proc. Soc. Exp. Biol. Med. 1959, 101:223-225.
111. Simmonds W.J., et al. Absorption of cholesterol from a micellar solution: intestinal perfusion studies in man. J. Clin. Invest. 1967, 46:874-890.
112. Grunhage F., et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 2007, 46:793-801.
113. Peng D., et al. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J. Pharmacol. Exp. Ther. 2008, 327:332-342.
114. Kuivenhoven J.A., et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 2005, 95:1085-1088.
115. Cannon C.P., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 2010, 363:2406-2415.
116. Degoma E.M., Rader D.J. Novel HDL-directed pharmacotherapeutic strategies. Nat. Rev. Cardiol. 2011, 8:266-277.
117. McNamara D.J., et al. Heterogeneity of cholesterol homeostasis in man. Response to changes in dietary fat quality and cholesterol quantity. J. Clin. Invest. 1987, 79:1729-1739.
118. Wang X., et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 2007, 117:2216-2224.
119. de Boer J.F., et al. Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice. J. Lipid Res. 2012, 53:348-357.
120. Stange E.F., Dietschy J.M. Cholesterol synthesis and low density lipoprotein uptake are regulated independently in rat small intestinal epithelium. Proc. Natl. Acad. Sci. U.S.A. 1983, 80:5739-5743.